Sandoz generic divestitures
Executive Summary
Sandoz and Eon will divest three generic drugs as part of Novartis' acquisition of Eon: Sandoz' desipramine and orphenadrine, and Eon's rifampin. Together, the three products generated 2004 revenue of less than $5 mil., Sandoz said. The divestitures are expected to close July 22. The Federal Trade Commission is continuing to review the acquisition; Novartis has submitted a second response to the agency, and the deal is expected to close by the end of July. Novartis announced its $8.76 bil. acquisition of Eon and Hexal in February (1"The Pink Sheet" Feb. 28, 2005, p. 21)...
You may also be interested in...
Novartis wraps up Eon
Sandoz, Hexall AG and newly added Eon Labs are expected to generate more than 80 generic approvals per year, the parent company says July 21. Novartis completed the acquisition of Eon two days after receiving clearance from the Federal Trade Commission. Under a proposed consent order with FTC, Novartis agreed to divest three generic drugs - Sandoz' muscle relaxant orphenadrine and tuberculosis treatment rifampin, and Eon's antidepressant desipramine - to Amide Pharmaceuticals. "The Pink Sheet" (1July 18, In Brief) incorrectly identified desipramine as a Sandoz drug and rifampin as an Eon product...
Novartis Seeks To Be Generics “Powerhouse” With Eon, Hexal Acquisitions
Novartis expects the addition of Eon Labs and Hexal AG to its Sandoz division to create a generic drug "powerhouse" that will play a major role in the emerging "authorized" generics and follow-on biologics markets
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.